https://www.selleckchem.com/pr....oducts/golvatinib-e7
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended for adults acute lymphoblastic leukemia (ALL) with minimal residual disease (MRD) negative during their first complete remission (CR1). However, the role of pre-transplant consolidation chemotherapy remains unclear. We evaluated 78 CR1/MRD-negative patients, the consolidation and non-consolidation groups had similar 5-year OS (74.8% [95% CI 62.2-87.3%] vs. 74.2% [95% CI 53.2-95.1%], p = .894), RFS (72.2% [95% CI 59.6-84.7%] vs. 73.1% [95% CI 54.2-91.9
Tycka om
Kommentar
Dela med sig
